Racheli Ofir of Betalin Therapeutics

About this episode

Racheli Ofir discusses Betalin Therapeutics' innovative approach to treating insulin-dependent diabetes with a biological micropancreas.

Racheli Ofir is the CEO and CTO of Betalin Therapeutics, an Israeli company developing a biological micropancreas that could one day offer a one-time cure for insulin-dependent diabetes — replacing the missing pancreatic function with living cells that sense glucose and respond in real time. Avraham sat down with Racheli to discuss how the technology works, what their animal trials showed, why IP is critical, the challenges of funding a biotech startup in wartime Israel, her advice for founders just getting started and much more. Do you have a great innovation? We'd love to hear from you. Contact us by going to https://jmbdavis.com/startup/contact. Learn more at https://jmbdavis.com and https://jmbdavis.com/startup. Also available at https://soundcloud.com/jmbdavis/ betalin. Listen to all of the episodes at https://jmbdavis.com/podcast.

People in this episode

Host: Avraham

Guest: Racheli Ofir

Topics covered

• biotechnology
• diabetes treatment
• startup challenges
• innovation
• funding
• intellectual property

Keywords

• insulin-dependent diabetes
• biological micropancreas
• biotech startup
• funding challenges
• intellectual property
• animal trials
• Israeli technology

Mentioned in this episode

Organizations: Betalin Therapeutics

Products: biological micropancreas

Places: Israel

More episodes of Israeli Technology Founders Speak: Conversations with Successful Israeli Hitech and Biotech Entrepreneurs

• Chen Neeman of Enqode · April 30, 2026 · 16 min
• Sharon Barak of Solutum · March 26, 2026 · 19 min
• Baruch Halpert of Electriq · February 26, 2026 · 24 min
• Dr. Hadas Ziso of EndoCure · January 29, 2026 · 20 min
• Steve Grun of MNDL Bio · December 30, 2025 · 27 min
• Hanan Brand head of the Startup Division Israel Innovation Authority · November 26, 2025 · 26 min